Regeneron Pharmaceuticals Hits New 52-Week High on Earnings Beat (REGN)
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) hit a new 52-week high during trading on Tuesday following a stronger than expected earnings report, Stock Ratings News reports. The company traded as high as $325.39 and last traded at $324.01, with a volume of 2,459,929 shares traded. The stock had previously closed at $304.00.
The company reported $2.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.97 by $1.27. The company had revenue of $610.00 million for the quarter, compared to the consensus estimate of $579.17 million. During the same quarter in the previous year, the company posted $1.47 earnings per share. The company’s revenue for the quarter was up 47.0% on a year-over-year basis.
Several analysts have recently commented on the stock. Analysts at TheStreet reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. Regeneron Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $305.66.
In other Regeneron Pharmaceuticals news, major shareholder Sanofi acquired 168,511 shares of the stock in a transaction dated Friday, February 7th. The shares were purchased at an average price of $286.78 per share, with a total value of $48,325,584.58. The transaction was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
The stock’s 50-day moving average is $282.5 and its 200-day moving average is $279.8. The company has a market cap of $31.771 billion and a P/E ratio of 43.28.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.